Back
HFA Premium Access

Effects of empagliflozin on exercise capacity and LV diastolic function in HFpEF and type-2 diabetes mellitus: rationale and design of prospective intervention study

Session: Poster Session 3 - Chronic Heart Failure – Treatment
Topic: Pharmacotherapy
Speaker: Doctor A. Borisov (Moscow, RU)
Event: Heart Failure 2019

Congress Presentation

Add to my library

Like

About the speaker

Doctor Anton Borisov

National Medical Research Center for Cardiology, Moscow (Russian Federation)
0 follower

56 more presentations in this session

Effects of mineralocorticoid ceceptor antagonists (MRA) in heart failure patients after up to 12 months of follow-up.

Speaker: Doctor L. Buttigieg (Msida, MT)

Access
Abstract
Like
Thumbnail

Sacubitril valsartan, a multicentric experience

Speaker: Mr F. Cortes (Sevilla, ES)

Access
Abstract
Like
Thumbnail

Reduction of NT-proBNP in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction in short-term treatment with empagliflozin on top of existing therapy

Speaker: Professor B. Kanazirev (Varna, BG)

Access
Abstract
Slides
Like
Thumbnail

Effects of sacubitril/valsartan on real-world patients with heart failure due to non-ischemic cardiomyopathy

Speaker: Associate Professor C. Hsu (Taipei, TW)

Access
Abstract
Slides
Like
Thumbnail

Effects of ivabradine on patients with depressed left ventricular ejection fraction after cardiac resynchronization therapy

Speaker: Doctor C. Hsieh (Taipei, TW)

Access
Abstract
Like
Thumbnail

Access the full session

Poster Session 3 - Chronic Heart Failure – Treatment

Speakers: Doctor A. Borisov, Doctor L. Buttigieg, Mr F. Cortes, Professor B. Kanazirev, Associate Professor C. Hsu...
Access
Like
Thumbnail

About the event

Image

Heart Failure 2019

25 May - 28 May 2019

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources